

## APPOINTMENT OF NON EXECUTIVE DIRECTOR

**May 14, 2021. Melbourne, Australia.**

Rhinomed Limited (ASX:RNO OTCQB:RHNMF) a leader in wearable nasal and respiratory technology is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately.

Assoc. Prof. McBain is the former Head of Reproductive Services at The Royal Women's Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was a founder of Melbourne IVF, now Virtus Health (ASX:VRT). Assoc. Prof. McBain served as a Director of Melbourne IVF and subsequently as a Director of Virtus Health prior to its listing on the ASX. Assoc. Prof. McBain holds a Medical degree from Glasgow University.

Assoc. Prof. McBain is currently a Non Executive Director of AP Ventures.

Chairman Ron Dewhurst said, "On behalf of my fellow Directors and shareholders, I welcome John to the Board of Rhinomed Ltd. John, with his wealth of knowledge and experience in the medical field will be invaluable during an expected period of growth for the Company. Assoc. Prof. McBain's appointment further compliments the Board's existing skillset and experience."

This report has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 <a href="mailto:mjohnson@rhinomed.global">mjohnson@rhinomed.global</a> Follow us on <b>Twitter</b> @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

Follow us on **Twitter** @rhinomedceo and @theturbinecom

**Rhinomed Global** (<https://www.rhinomed.global>) is an Australian-based medical technology company with a patented nasal technology platform whose first products are used by consumers in the global sleep, respiration, and nasal congestion markets. These products, sold at major US retailers, support the development, acceptance, and adoption of a pipeline of future wearable, sensor, diagnostic, and drug delivery opportunities. The company has recently secured FDA class 1 registration for its Rhinoswab, a dual nostril swab designed to collect nasal specimens for diagnostic testing for respiratory diseases, particularly COVID-19.

Since its formation six years ago, Rhinomed has built the necessary foundation to accelerate its already increasing revenue growth. The company trades on the **ASX:RNO** and the **OTCQB:RHNMF**.